Table 1.

Clinical activity of talimogene laherparepvec in advanced melanoma.

	Phase II T-VEC study	Phase III T-VEC study
Patient numbers	50	295 (T-VEC arm)
Stage	IIIc, 20% IVa, 32% IVb, 8% IVc, 40%	IIIb/c, 30% IVa, 27% IVb, 21% IVc, 22%
Objective response rate	26%	26.4% (16.3% durable response rate)
Overall survival	58% 1 year 52% 2 year	23.3 months (median)
Toxicities	Grade 1–2: fever 52%, chills 48%, fatigue 32%, nausea 30% No Grade 3 AEs noted	All grades: fatigue 50%, chills 49%, fever 43%, nausea 36% Grade 3/4: cellulitis 2%, fatigue 2%, vomiting 2%, dehydration 2%
NCT trial ID, Reference	NCT00289016 [27]	NCT00769704 [29]

T-VEC: Talimogene laherparepvec.